Watch our webinars and symposiums aim to provide the latest information on Phenylketonuria (PKU). Listen from your peers on how PKU management and treatment is evolving and update your preferences in your account to be notified when we have new content available.
Expert Talks
In this video, Prof Alvaro Hermida (University of Santiago de Compostela, Santiago, Spain) discusses some of the comorbidities that are seen in adult PKU patients and the challenges that may be involved in their management, including overviews of neuropyschiatric issues, bone health, and cardiovascular risk.
Time: 20:28
Veeva code: EU-PKU-00477
Expert Talks
Dr Stephan Huijbregts (Leiden University, the Netherlands) examines the neurocognitive aspects of PKU, including how changes in Phe levels can impact cognitive ability, the neurocognitive and psychosocial functioning of adolescents and adults with PKU, and possible future directions for the assessment of neurocognitive aspects of PKU.
Time: 10:12
Veeva code: EU-PAL-00478
Expert Talks
In this video, Dr Mark Walterfang (Royal Melbourne Hospital, Melbourne Neuropsychiatry Centre, University of Melbourne, Florey Institute of Neuroscience and Mental Health, Melbourne, Australia) talks about the “Cognitive, Psychiatric and MRI changes in adults who improve Phe control”. Dr Walterfang reviews the pathophysiology of PKU and how this predisposes patients to both psychiatric illness and cognitive change. He examines how psychiatric illness is over-represented in PKU (but is often treatable), discusses how cognitive change can be more severe when Phe control is poor or absent, and looks at whether individuals who have ceased the PKU diet previously can show improvements in cognitive and psychiatric function through careful management and improved Phe control.
Time: 21:26
Veeva code: EU-PAL-00476
Expert Talks
In this video, Dr Cary Harding (Oregon Health & Science University, Portland, OR, USA)discusses how individuals with hyperphenylalaninemia are often unaware of neurocognitive impairments until they have been effectively treated. He reviews how neuropsychological outcomes have been assessed in pharmaceutical trials, the limitations of outcome measures that are determined by self-assessment, and the need for future studies to catalogue functional outcomes.
Time: 19:00
Veeva code: EU-MPRL-PKU-00081